Sai Life Sciences IPO
GMP, Subscription, Price, Dates & Financial Details
Sai Life Sciences Limited is an innovator-focused contract research, development, and manufacturing organization (CRDMO) that provides end-to-end services across the drug discovery, development, and manufacturing value chain. It supports small molecule new chemical entities (NCEs) for global…
Open Date
Wed, 11 Dec 2024
Close Date
Fri, 13 Dec 2024
Price Band
₹ 522 – 549
Lot Size
27
Issue Size
₹ 3,042.62 Cr
Minimum Investment
₹ 14,823 (27 Shares)
Grey Market Premium Analysis
Day Wise GMP→Unofficial premium quoted in the grey market, tracked daily against the price band cap.
Grey market trading is unregulated. GMP figures are indicative only and should not be the sole basis for investment decisions - treat as a sentiment indicator, not a guarantee.
IPO Details
Sai Life Sciences IPO has successfully completed its IPO process and is now listed on the NSE and BSE. According to the Red Herring Prospectus (RHP), the IPO was a book-built issue with a total issue size of ₹3,042.62 Crore, comprising a fresh issue of 1.73 Crore equity shares aggregating to ₹950.00 Crore and an offer for sale (OFS) of 3.81 Crore equity shares aggregating to ₹2,092.62 Crore by the existing shareholders.
The Sai Life Sciences IPO remained open for subscription from December 11, 2024, to December 13, 2024. The basis of allotment was finalized on December 16, 2024, and the company's shares were listed on the NSE and BSE on December 18, 2024.
The company had fixed the price band at ₹522 to ₹549 per share, with a lot size of 27 shares. Retail investors were required to make a minimum investment of ₹14,823 (based on the upper price band) to apply for one lot.
KFin Technologies Limited served as the registrar to the issue. Morgan Stanley India Company Private Limited, Jefferies India Private Limited, Kotak Mahindra Capital Company Limited, and IIFL Capital Services Limited acted as the Book Running Lead Managers (BRLMs) to the issue.
With the successful completion of the IPO process, Sai Life Sciences Limited is now a publicly listed company on the NSE and BSE. Investors can track the company's share price, trading performance, financial results, and corporate announcements through the stock exchanges.
Sai Life Sciences IPO Timeline (Tentative)
- IPO Open Date
- Wed, 11 Dec 24
- IPO Close Date
- Fri, 13 Dec 24
- Basis of Allotment
- Mon, 16 Dec 24
- Initiation of Refunds
- Tue, 17 Dec 24
- Credit of Shares to Demat
- Tue, 17 Dec 24
- Listing Date
- Wed, 18 Dec 24 — NSE & BSE
Open Date
11 December 2024
Close Date
13 December 2024
Basis Of Allotment
16 December 2024
Listing Date
18 December 2024
IPO Subscription
Check Live Subscription →The Sai Life Sciences IPO has received bids for 39,85,59,636 shares against 3,88,29,848 shares offered, resulting in an overall subscription of 10.26x. the NII category is subscribed 4.92x, Retail Investors 1.37x, and QIBs 30.93x. Within the NII category, BNII is subscribed 6x, while SNII is subscribed 2.74x.
QIB
30.93x
NII
4.92x
BNII
6x
SNII
2.74x
RII
1.37x
Total
10.26x
IPO Reservations
The Retail Individual Investor (RII) category has the highest allocation with 1,93,97,392 shares, representing 35% of the total issue. Qualified Institutional Buyers (QIBs) are allocated 1,10,84,225 shares (20%), while Non-Institutional Investors (NIIs) receive 83,13,168 shares (15%).
| Category | Shares Offered | Shares Offered % |
|---|---|---|
| Anchor Investors | 16,626,336 | 30% |
| Qualified Institutions | 11,084,225 | 20% |
| Non-Institutional | 8,313,168 | 15% |
| BNII | 5,542,113 | 10% |
| SNII | 2,771,056 | 5% |
| Retail Investors | 19,397,392 | 35% |
| Total | 55,421,121 | 100% |
Financials Details(₹ in Crores)
| Particular | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 2476.78 | 2275.14 | 2186.65 | 2164.23 |
| Revenue | 693.35 | 1494.27 | 1245.11 | 897.74 |
| Profit After Tax | 28.01 | 82.81 | 9.99 | 6.23 |
| Net Worth | 1044.75 | 974.34 | 887.29 | 877.76 |
| Reserve & Surplus | 855.69 | 953.99 | 867.43 | 859.17 |
| Total Borrowings | 764.49 | 710.16 | 699.23 | 751.32 |
Financials Performance
Performance Indicators
EPS Pre
Earnings per share before the IPO.
P/E Pre
IPO Offer Price ÷ EPS Pre.
EPS Post
Expected earnings per share after the IPO..
P/E (Post Issue)
IPO Offer Price ÷ EPS Post.
Sai Life Sciences Limited KPI Information
| Particular | KPI as of March 31, 2024. |
|---|---|
| ROE % | 11.79 |
| ROCE % | 15.96 |
| RoNW % | 8.13 |
| PbW | 10.18 |
| Pat Margin % | 5.65 |
Peers Comparison
No Peer Comparision Available
About Sai Life Sciences Limited
Sai Life Sciences Limited is an innovator-focused contract research, development, and manufacturing organization (CRDMO) that provides end-to-end services across the drug discovery, development, and manufacturing value chain. It supports small molecule new chemical entities (NCEs) for global pharmaceutical and biotechnology firms. The company offers both contract research (CRO) and contract development and manufacturing (CDMO) capabilities.
Sai Life Sciences is one of the fastest-growing Indian CRDMOs in terms of revenue and EBITDA growth from FY 2022 to FY 2024. It serves over 280 pharmaceutical companies globally, including 18 of the top 25 pharmaceutical firms, with a significant presence in regulated markets like the US, UK, Europe, and Japan.
The company operates with research labs in innovation hubs like Greater Boston, US, and Manchester, UK, along with large-scale manufacturing facilities in India. This combination of global reach and cost-effective Indian operations allows Sai Life Sciences to support customers at various stages of the drug discovery-to-commercialization process.
Sai Life Sciences provides integrated CRO services in biology, chemistry, and drug metabolism, and has contributed to the approval of drugs and IND filings. In the CDMO space, it develops and manufactures active pharmaceutical ingredients (APIs) and intermediates for both clinical and commercial phases, including for blockbuster drugs.
The company has a diversified portfolio of over 170 innovator pharmaceutical products, including late-phase and early-phase drugs. It serves a broad customer base, with no single customer accounting for more than 8% of revenue. Its manufacturing facilities are accredited by global regulatory agencies, such as the USFDA and PMDA, Japan.
Sai Life Sciences is committed to sustainability, with initiatives aimed at energy conservation, increased use of renewable energy, and environmental protection. It has received a silver sustainability rating from EcoVadis and is a member of the Pharmaceutical Supply Chain Initiative (PSCI).
The company is led by an experienced management team, supported by investors like TPG Asia and HBM Private Equity India, and has a strong focus on corporate governance and environmental, social, and governance (ESG) strategies. As of September 2024, it employs over 3,100 staff, including a large team of scientists and engineers.
Sai Life Sciences IPO Promoters
- Kanumuri Ranga Raju
- Krishnam Raju Kanumuri
- Kanumuri Mytrey
- Sai Quest Syn Private Limited
- Sunflower Partners
- Lily Partners
- Marigold Partners
- Tulip Partners
Promoters Holding
Holding Pre Issue
40.48%
Holding Post Issue
35.10%
Sai Life Sciences IPO Objective
The company propose to utilise the Net Proceeds towards funding the following objects:
- Repayment/prepayment in full or part, of all or certain outstanding borrowings availed by the Company and
- General corporate purposes
Sai Life Sciences Limited Address / Contact Details
Sai Life Sciences Limited
Plot No. DS- 7, IKP Knowledge Park,
Turkapally Village, Shameerpet Mandal,
Medchal – Malkajgiri
District, Hyderabad 500 078,
Telangana
Phone: +9140 6815 6000
Email: investors@sailife.com
Website: https://www.sailife.com/
IPO Snapshot
Sai Life Sciences IPO Lot Size
The Sai Life Sciences IPO has a lot size of 27 shares. Retail investors require a minimum investment of ₹14,823 by applying for 1 lot (27 shares). The maximum application allowed for the retail category is 13 lots (351 shares), requiring an investment of ₹1,92,699.
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 27 | 14,823.00 |
| Retail (Max) | 13 | 351 | 192,699.00 |
| S-HNI (Min) | 14 | 378 | 207,522.00 |
| S-HNI (Max) | 67 | 1,809 | 993,141.00 |
| B-HNI (Min) | 68 | 1,836 | 1,007,964.00 |
Issue Reservation
- Anchor Investors — 30%
- QIB — 20%
- NII — 15%
- RII — 35%
Book Running Lead Managers
- Morgan Stanley India Company Private Limited
- Jefferies India Private Limited
- Kotak Mahindra Capital Company Limited
- IIFL Capital Services Limited
IPO Documents & Links
Explore More IPOs
Currently Open
Coming Up Next
Disclaimer: This data is for informational purposes only and does not constitute investment advice.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
What is the Sai Life Sciences IPO?
Sai Life Sciences IPO is a Book-building IPO with a total issue size of ₹3042.62 crore. The Sai Life Sciences IPO price band is ₹522 to 549 per share. The Sai Life Sciences IPO subscription opens on Wed, Dec 11, 2024, and closes on Fri, Dec 13, 2024. The Sai Life Sciences IPO will be listed on the BSE,NSE. KFin Technologies Limited is the registrar for the Sai Life Sciences IPO.
When will the Sai Life Sciences IPO open for subscription?
The Sai Life Sciences IPO opens on Wed, Dec 11, 2024 and closes on Fri, Dec 13, 2024
What is Sai Life Sciences IPO Price Band?
Sai Life Sciences IPO Price Band is ₹522 to 549 per share.
What is Sai Life Sciences IPO Lot Size?
Sai Life Sciences IPO lot size is 27 shares, Retail investors need a minimum investment of ₹14823 based on the upper price band
What is the minimum investment for Sai Life Sciences IPO?
The minimum investment for Sai Life Sciences IPO is ₹14823, based on one lot of 27 shares at the upper price band of ₹549 per share.
How to apply for Sai Life Sciences IPO?
Investors can apply for the Sai Life Sciences IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Fri, Dec 13, 2024. The application amount remains blocked until the Sai Life Sciences IPO allotment is finalized.
What is Sai Life Sciences IPO Issue Size?
Sai Life Sciences IPO issue size is ₹3042.62 crores.
What is the Sai Life Sciences IPO Allotment Date?
Sai Life Sciences IPO allotment date is Mon, Dec 16, 2024.
Who is the Sai Life Sciences IPO Registrar?
The registrar for Sai Life Sciences IPO is KFin Technologies Limited. Investors can go to KFin Technologies Limited website to check Sai Life Sciences IPO allotment status, refund processing, and other IPO-related information.
What is the Sai Life Sciences IPO GMP?
The Sai Life Sciences IPO GMP (Grey Market Premium) is ₹72 as of Wed, Dec 18, 2024. Based on the upper price band of ₹549 per share, the estimated Sai Life Sciences IPO listing price is ₹621, indicating a potential listing gain of approximately 13.11% over the issue price.
Who is the Sai Life Sciences IPO Lead Manager?
The book-running lead managers (BRLMs) for the Sai Life Sciences IPO are Morgan Stanley India Company Private Limited, Jefferies India Private Limited, Kotak Mahindra Capital Company Limited, and IIFL Capital Services Limited. The lead managers are responsible for managing the IPO process, including issue structuring, regulatory compliance, marketing the public issue, coordinating with investors, and ensuring a smooth listing process. For complete details, investors should refer to the Sai Life Sciences IPO Red Herring Prospectus (RHP).